ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 7, 2002, Pages 2179-2184

  Naeger, Lisa K ^a   Margot, Nicolas A ^a   Miller, Michael D ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADENOSINE TRIPHOSPHATE; AMDOXOVIR; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE;

ARTICLE; DRUG SENSITIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; CATALYSIS; DRUG EFFECT; METABOLISM; MUTATION; PHYSIOLOGY; VIRUS REPLICATION;

ADENINE; ADENOSINE TRIPHOSPHATE; ANTI-HIV AGENTS; CATALYSIS; DRUG RESISTANCE, VIRAL; HIV-1 REVERSE TRANSCRIPTASE; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; VIRUS REPLICATION; ZIDOVUDINE; PHOSPHONIC ACIDS;

EID: 0035984790     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.7.2179-2184.2002     Document Type: Article

References (32)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. Luminescent immobilized enzyme test systems for inorganic pyrophosphate: Assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5′-triphosphate sulfurylase
3. On the fidelity of DNA replication. Lack of exodeoxyribonuclease activity and error-correcting function in avian myeloblastosis virus DNA polymerase
4. HIV-1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
5. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase
6. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer
7. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate
8. Comparative kinetic analysis of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases
9. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
10. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine
11. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
12. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
13. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
14. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: Implication of RNA directed DNA polymerization in the mechanism of AZT resistance
15. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC
16. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay
17. Stavudine resistance: An update on susceptibility following prolonged therapy
18. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
19. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
20. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates
21. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
22. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF therapy: 48 week genotypic analysis of study 902
23. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
24. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
25. Altered drug susceptibility of HIV-1 RT mutants containing M184V and zidovudine-resistance mutations: Analysis of RT processivity, viral replication, and chain-terminator removal
26. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
27. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
28. The accuracy of reverse transcriptase from HIV-1
29. Metabolism of inorganic pyrophosphate (PPi)
30. Mutations in retroviral genes associated with drug resistance: 2000-2001 update
31. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy
32. Physiological concentrations of purines and pyrimidines